RxDoctor Payments Data

Zachary Marwil, MD

Gastroenterology · Wantagh, NYNPI 1609002229

Payments from drug & device makers

$9,575in general payments, 2019–2025

Across 473 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$858
  • Nestle Healthcare Nutrition Inc.$747
  • Takeda Pharmaceuticals U.S.A., Inc.$553
  • Pfizer$301
  • plus $3K from 33 others

What the payments were for

  • Consulting fees$360%
  • Food & beverage$9,44099%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,575 in reported general payments places this provider in the 75th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$118,795
Medicare patients
359
Services billed
756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab32$855,848
EntyvioVedolizumab13$111,015
XifaxanRifaximin13$63,761
CreonLipase/Protease/Amylase36$49,778
ZenpepLipase/Protease/Amylase23$33,764
LinzessLinaclotide17$22,781
Mesalamine59$19,025
Mesalamine ErMesalamine47$15,423
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates144$8,520
Budesonide14$6,450
Dexlansoprazole DrDexlansoprazole16$5,753
Pantoprazole Sodium316$3,434
Colestipol Hcl45$3,024
SutabSod Sulf/Pot Chloride/Mag Sulf16$2,536
Rabeprazole Sodium27$1,715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$858$855,84832 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$553$111,01513 claims
AbbVieCreon, Linzess$2,714$72,56053 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,244$63,76113 claims
Aimmune Therapeutics, Inc.Zenpep$50$33,76423 claims
Braintree Laboratories, Inc.Sutab$192$2,53616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Wantagh

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →